OpenEvidence

Why Trade the OpenEvidence Pre-IPO CFD, Access, Valuation Story, and Risk Factors

The case for trading the OpenEvidence pre-IPO CFD rests on three pillars: access that conventional private-market channels deny retail participants, a documented valuation re-rating story across successive primary rounds, and a risk profile distinct from ordinary equity trading. Each of these deserves precise treatment.

The Access Wedge

Private pre-IPO markets have historically been restricted to accredited investors. Platforms such as EquityZen, Forge Global, and Hiive typically require participants to meet income or net-worth thresholds, and minimum position sizes can run to tens of thousands of dollars.

Shares transact infrequently, settlement timelines are long, and the onboarding process mirrors that of a brokerage account with standard documentation requirements.

The CoinUnited pre-IPO CFD on OpenEvidence operates under a different model. Participation requires no accreditation, the minimum exposure starts from US$100, and the instrument trades 24/7 with no exchange session constraints or holiday gaps. The account is funded and withdrawn in crypto, bypassing the need for a traditional bank account.

Critically, what CoinUnited provides is synthetic price exposure via a contract for difference, not equity ownership. The CFD tracks the private-market reference price of OpenEvidence; it confers no shareholding, voting rights, dividends, or claim on IPO proceeds. These distinctions matter and should be understood before any position is opened.

The Valuation Re-Rating Narrative

OpenEvidence's primary-round marks, as reported by financial press across 2025 and into 2026, trace an unusually steep trajectory. A post-money valuation of approximately $1 billion was reported in February 2025. By July 2025, that figure had risen to roughly $3.5 billion. October 2025 brought a reported mark of approximately $6 billion.

By January 2026, a $250 million funding round was associated with a reported valuation of $12 billion, as cited by CNBC and Sacra, with that figure reiterated by CNBC in May 2026.

Each step in this progression reflects institutional willingness to pay higher prices for the same private equity at each subsequent round, a pattern driven by competitive demand among investors rather than a publicly traded price mechanism.

The re-rating from approximately $1 billion to $12 billion across roughly twelve months is notable within the 2025–2026 private AI funding environment, though it does not imply a guaranteed continuation of that trajectory.

Strategic Backer Quality

The investor roster adds a qualitative dimension to the valuation story. OpenEvidence's backers include Sequoia Capital, Kleiner Perkins, and Thrive Capital on the venture side; Nvidia and Google Ventures as corporate strategics; and Blackstone, DST Global, and Coatue representing large financial sponsors. The breadth across categories is meaningful.

Venture firms price and lead rounds based on company fundamentals and growth projections. Corporate strategics such as Nvidia typically invest where there is product-level conviction, not merely financial expectation. Financial sponsors like Blackstone bring different due diligence frameworks and tend to seek larger, more mature private positions.

When these distinct investor types converge on the same cap table, it historically correlates with sustained secondary-market demand, though it does not eliminate downside risk.

Risk Factors Specific to Pre-IPO CFD Trading

The risks here are material and specific to the instrument type, not just the underlying company.

IPO timing is uncertain. OpenEvidence has not announced a public listing date. An IPO may be delayed, restructured as a direct listing or SPAC transaction, or cancelled entirely. The CFD's reference price would be affected by any change in IPO expectations.

Secondary-market pricing is thin. As of mid-2026, no reliable public reporting exists on OpenEvidence secondary-market transaction prices. The most recent verifiable data point is the primary-round mark of $12 billion from January 2026. Traders should treat this as an indicative private-market reference, not a liquid exchange price.

The CFD is not equity. Holders of the CoinUnited instrument have no claim on OpenEvidence assets, earnings, or IPO allocations. The instrument's value is derived from price movement in the reference price, nothing else.

Leverage amplifies both gains and losses. Leveraged synthetic positions can result in losses exceeding the initial margin if the reference price moves adversely. Position sizing relative to available margin requires explicit management.

Private AI valuations are sentiment-sensitive. Broad market risk-off episodes, shifts in AI sector narrative, or competitive disruption from larger AI platform providers can compress private-market multiples rapidly. Primary-round marks reflect the last price a set of investors agreed to pay, subsequent marks may be higher or lower depending on conditions at the time of any future round.

Trading OpenEvidence (OPEN_EVIDENCE) on CoinUnited.io, Pre-IPO CFD Mechanics, Leverage, and Strategy

The OPEN_EVIDENCE instrument on CoinUnited is a CFD-style derivative that provides synthetic price exposure to OpenEvidence's private-market reference price. It is not equity. Opening a position confers no shareholding, no voting rights, no dividends, and no allocation in any future IPO.

What it does provide is directional exposure to how the market re-rates OpenEvidence's private valuation, upward or downward, without requiring a traditional brokerage account, accreditation status, or participation in a formal tender process.

Product Mechanics

The instrument tracks OpenEvidence's private-market reference price synthetically. CoinUnited's infrastructure is crypto-native: accounts are funded and withdrawn in cryptocurrency, so no traditional bank account is required and onboarding bypasses the documentation layers typical of conventional pre-IPO platforms or broker-dealers.

The minimum exposure starts from US$100, and the instrument trades 24 hours a day, seven days a week.

This contrasts materially with traditional pre-IPO access. On conventional secondary platforms, transactions in private company shares typically occur only at periodic tender events or structured liquidity windows, often quarterly at best, sometimes less frequently. The CoinUnited CFD imposes no such timing restriction.

A position can be opened or closed at any point, subject to available liquidity and spread conditions.

Important: eligibility to trade this instrument is subject to CoinUnited's terms and applicable restrictions. Geographic or regulatory availability should be verified directly with the platform before opening a position.

Leverage: Up to 100x

CoinUnited offers up to 100x leverage on the OPEN_EVIDENCE pre-IPO CFD. The mechanical relationship is direct: at 100x, a 1% move in the reference price produces a 100% gain or 100% loss on the margin deployed.

A worked example illustrates the arithmetic:

At 100x, the liquidation threshold is reached with a reference price move of approximately 1% against the position (before fees and funding adjustments). In a liquid public equity, a 1% intraday move is routine. In a private-market instrument, where the reference price reflects infrequent round-level marks and can gap significantly on news, the risk profile is more acute.

Position Sizing for Pre-IPO Volatility

Private-market price discovery for OpenEvidence is thinner than in public equity benchmarks. The valuation has moved from approximately $1 billion to $12 billion across roughly one year of funding rounds, reflecting episodic re-rating rather than continuous price formation.

This pattern is characteristic of late-stage private AI companies: long periods of stable marks punctuated by sharp re-ratings at new funding events.

For a leveraged CFD position, this creates gap risk, the reference price can reprice substantially between observable data points. Traders applying high leverage to a pre-IPO synthetic should account for this by:

• -Sizing positions so that total margin at risk represents a defined, limited fraction of available capital
• -Maintaining buffer margin well above the minimum to absorb interim volatility without triggering liquidation
• -Treating the position as high-variance by construction, not as a proxy for a liquid public stock

Primary Catalysts for Reference Price Movement

Because OpenEvidence does not publish earnings or trade on a public exchange, the reference price is driven by a narrower set of observable signals.

The principal catalysts include new primary funding rounds (which establish fresh valuation marks), strategic partnership announcements, regulatory developments affecting AI software companies, and any public disclosure related to an IPO filing or listing timeline. Each of these can produce discrete, non-linear moves in the reference price rather than gradual drift.

IPO Event Handling

If OpenEvidence proceeds to a public listing, the synthetic CFD position will be subject to CoinUnited's specific settlement, conversion, or closure terms as set out in the platform's product documentation.

The outcome for a CFD holder at an IPO event differs from the outcome for a holder of actual equity, IPO allocation, lock-up periods, and post-listing price discovery apply to shareholders, not to CFD counterparties. Traders should review CoinUnited's current product documentation before opening a position to understand precisely how an IPO event would affect their exposure.

Entry and Exit Considerations

Spreads on pre-IPO synthetic instruments reflect the illiquidity of the underlying private-market reference price. Entry and exit costs are wider than on comparable public-equity CFDs.

The practical implication is that short-duration trading strategies that rely on capturing small moves are less favorable in pre-IPO synthetics than in liquid markets; the spread represents a higher proportion of the anticipated price movement.

Positions sized with defined risk, held across identifiable catalyst windows, and closed with awareness of spread cost are better aligned with the structural characteristics of this instrument.